- Academic Editor
-
-
-
†These authors contributed equally.
Background: Menstrual cycle disorders represent a prevalent cause for
gynecological consultations. These disorders often encompass ovulatory
dysfunction, accompanied by analytical and clinical anomalies linked to
hyperandrogenism, collectively defining polycystic ovary syndrome (PCOS).
However, a considerable subset of patients suffering from menstrual cycle
disorders fails to meet the diagnostic criteria for any recognized PCOS
phenotypes, leading to substantial debate in the field. This study aims to assess
the impact of a commercially available combination of inositols, melatonin, folic
acid, and vitamin D in patients experiencing menstrual disorders, characterized
by oligo-anovulation (amenorrhea and abnormally long cycles), irrespective of
their actual compliance with PCOS criteria. Methods: An observational,
prospective, non-randomized study was devised to assess cycle regularity,
satisfaction levels, and analytical alterations following the administration of
the combination of inositols, melatonin, folic acid, and vitamin D (at baseline
and at 6 months). Statistical analysis was executed using SPSS (version 22.0). Results:
The assessed treatment demonstrated an enhancement in the regularity of menstrual
cycles, accompanied by notable reductions in androstenedione and
dehydroepiandrosterone (DHEA) levels, as well as basal insulin and the
homeostatic model assessment for insulin resistance (HOMA), despite their initial
values falling within the normal range. Furthermore, there was a substantial
elevation in the serum levels of vitamin D (p